Skip to content
Screener

Harrow HROW Q2 2026 earnings

Reported August 10, 2026 · After market close

Revenue$70.7MBeat by $310.9K
EPS-$0.46Miss by $0.28
Revenue estimate$70.4M
EPS estimate-$0.18
“We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability. Over the past six months, we expanded our commercial organization, strengthened our portfolio, improved pricing across key products, launched BYOOVIZ®, advanced multiple clinical programs, and announced the acquisition of TYRVAYA. VEVYE delivered record quarterly revenue while improving its underlying economics, and momentum continues to build, supported by our recent coverage win that went into effect August 1. IHEEZO achieved the strongest commercial quarter in its history despite the loss of pass-through reimbursement, and TRIESENCE continued to generate exceptional demand growth – reinforcing our conviction that physician demand continues to strengthen across our portfolio.”
Mark L. Baum

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$99.1M
EPS estimate$0.16

Financials

Q2 2026

Income statement

See full
Revenue$70.7M+10.9%
Gross profit$50.4M+6.0%
Operating income-$11.0M-196%
Net income-$17.3M-446%
EPS (diluted)-$0.46-454%

Balance sheet

See full
Cash & equivalents$83.9M+58.4%
Total debt$308.4M-32.0%
Total equity$15.2M-69.4%
Total assets$416.8M+20.8%

Cash flow

See full
Operating cash flow-$9.8M—
CapEx$491.0K+196%
Free cash flow-$10.2M—

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.27B-19.7%
Enterprise value$1.49B-24.6%
P/S4.6×-2.3×

Profitability

See full
Gross margin73.3%-1.3pp
Operating margin-1%-7.3pp
FCF margin1.8%+1.3pp

Returns & leverage

See full
Debt / equity20.3×+11.2×
Current ratio2.2×+1.6×

Segments

By product

See full
VEVYE$29.4M+57.6%
IHEEZO$15.6M-14.8%
Other branded products$11.0M+111%
Other revenues$90.0K—

By segment

See full
Branded$56.1M+32.7%
Compounding$14.6M-32.2%

FAQ

When did Harrow report Q2 2026 earnings?
Harrow (HROW) reported Q2 2026 earnings on August 10, 2026 after market close.
What were Harrow's Q2 2026 revenue and EPS?
Harrow reported revenue of $70.7M and eps of $-0.46 for Q2 2026.
Did Harrow beat estimates in Q2 2026?
Revenue beat the consensus estimate of $70.4M by $310.9K. EPS missed the consensus estimate of $-0.18 by $0.28.
How did Harrow's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.9% from $63.7M a year earlier.
Where can I find Harrow's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001493152-26-036865) and the 10-Q periodic report (0001628280-26-055271) directly on SEC EDGAR. The filing index links above go to sec.gov.